Reply to A. Ota et al, Y.H. Kim, and N. Van Der Steen et al-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Reply to A. Ota et al, Y.H. Kim, and N. Van Der Steen et al

Published:2017-02-20 Issue:6 Volume:35 Page:694-695
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Yang James Chih-Hsin¹,Puri Tarun¹,Orlando Mauro¹,Cheng Ying¹

Affiliation:

1. James Chih-Hsin Yang, National Taiwan University Hospital, Taipei, Taiwan; Tarun Puri, Eli Lilly, Gurgaon, Haryana, India; Mauro Orlando, Eli Lilly Interamérica, Buenos Aires, Argentina; and Ying Cheng, Jilin Provincial Cancer Hospital, Changchun, China

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2016.70.6978

Reference13 articles.

1. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Chemotherapy: A Glimmer of Hope?

2. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

3. Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer

4. Unconvincing Benefit of Combination Therapy With Gefitinib and Pemetrexed in Advanced Non–Small-Cell Lung Cancer

5. Gefitinib Plus Pemetrexed As First-Line Treatment in Patients With Nonsquamous Non–Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP